FindTrial
Sign In

The mechanism of SMYD3 promotes cisplatin resistance in ovarian cancer

The mechanism of SMYD3 promotes cisplatin resistance in ovarian cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000041222
Enrollment
Unknown
Registered
2020-12-22
Start date
2020-12-23
Completion date
Unknown
Last updated
2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

DDP resistance vs DDP sensitivity:Nil

Sponsors

Cancer Hospital Affiliated to Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients.

Exclusion criteria

Exclusion criteria: Patients with other tumors.

Design outcomes

Primary

MeasureTime frame
SMYD3;—

Countries

China

Contacts

Public ContactHongwei Lyu

Cancer Hospital Affiliated to Zhengzhou University

hongweilv@163.com+86 18203657380

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026